Compare MedCap AB with Similar Stocks
Dashboard
1
High Management Efficiency with a high ROE of 14.67%
2
The company is Net-Debt Free
3
Healthy long term growth as Operating profit has grown by an annual rate 30.65%
4
Positive results in Jun 26
5
With ROE of 15.00%, it has a attractive valuation with a 5.24 Price to Book Value
6
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
SEK 7,752 Million (Small Cap)
35.00
NA
0.00%
-0.09
15.00%
5.08
Revenue and Profits:
Net Sales:
606 Million
(Quarterly Results - Jun 2026)
Net Profit:
69 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
4.72%
0%
4.72%
6 Months
-2.02%
0%
-2.02%
1 Year
-20.33%
0%
-20.33%
2 Years
-3.44%
0%
-3.44%
3 Years
73.05%
0%
73.05%
4 Years
153.21%
0%
153.21%
5 Years
146.76%
0%
146.76%
MedCap AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
20.86%
EBIT Growth (5y)
30.65%
EBIT to Interest (avg)
10.33
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.16
Sales to Capital Employed (avg)
1.30
Tax Ratio
23.27%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
21.15%
ROE (avg)
14.67%
Valuation key factors
Factor
Value
P/E Ratio
35
Industry P/E
Price to Book Value
5.24
EV to EBIT
25.44
EV to EBITDA
16.59
EV to Capital Employed
5.65
EV to Sales
3.62
PEG Ratio
3.65
Dividend Yield
NA
ROCE (Latest)
22.20%
ROE (Latest)
15.00%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
606.30
521.70
16.22%
Operating Profit (PBDIT) excl Other Income
138.30
113.00
22.39%
Interest
13.50
6.90
95.65%
Exceptional Items
0.00
-4.00
100.00%
Consolidate Net Profit
69.10
53.70
28.68%
Operating Profit Margin (Excl OI)
153.10%
151.20%
0.19%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 16.22% vs 13.98% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is 28.68% vs -5.95% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
2,108.00
1,806.70
16.68%
Operating Profit (PBDIT) excl Other Income
432.70
345.90
25.09%
Interest
31.50
18.50
70.27%
Exceptional Items
0.50
21.10
-97.63%
Consolidate Net Profit
220.70
209.20
5.50%
Operating Profit Margin (Excl OI)
142.40%
135.30%
0.71%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 16.68% vs 13.82% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 5.50% vs 21.28% in Dec 2024
About MedCap AB 
MedCap AB
Pharmaceuticals & Biotechnology
MedCap AB (publ) is a Sweden-based private equity company engaged in investments in and development of companies active primarily within the medical equipment sector. The Company reports four segments: Abilia, Unimedic, Quickels and Inpac. The Company’s portfolio includes such companies as Abilia AB, which is engaged in the development and marketing of aids within the fields of communication, cognition, noise and environmental control; Unimedic AB, engaged in contract manufacturing of liquid pharmaceuticals; Quickels Systems AB, which is engaged in the development and marketing of intensive medical care equipment, such as care bags and electrocardiogram (ECG) equipment; AirContainer Package System AB that offers a wide range of packaging solutions for the pharmaceutical industry, and Dunmedic AB, which offers medical products, medicines and food supplements.
Company Coordinates 
Company Details
Sundbybergsvagen 1 , SOLNA None : 171 73
Registrar Details






